OCUL241115C12500
- 0.22
- +0.02+10.00%
Ocular Therapeutix Newsroom
Piper Sandler Remains a Buy on Ocular Therapeutix (OCUL)
Baird Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $17
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Ocular Therapeutix Price Target Announced at $22.00/Share by Scotiabank
Scotiabank Initiates Ocular Therapeutix at Sector Outperform
Ocular Therapeutix Analyst Ratings
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $14
BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Buy Rating on Ocular Therapeutix: Accelerated Phase 3 Trial Enrollment and Promising 2025 Outlook
Express News | Ocular Therapeutix Inc - Topline Data From Sol-1 Expected in Q4 2025
Express News | Ocular Therapeutix Inc - Sol-1 Expected to Be Fully Randomized by Year-End 2024
Ocular Therapeutix Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI in Wet AMD
Express News | Ocular Therapeutix™ Announces Accelerated Timelines for Sol-1 Registrational Trial of Axpaxli™ in Wet AMD
Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
Ocular Therapeutix Expands Stock Incentive Plan for Employees
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Piper Sandler analyst Biren Amin maintains $Ocular Therapeutix(OCUL.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 42.5%
Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)
Ocular Therapeutix to Present at Two Investor Conferences in September